MedwellAI Enters Final Due Diligence for Apollo Biowellness Acquisition

MedwellAI (MWAI) has announced it is currently reviewing the final due diligence for its planned acquisition of Apollo Biowellness (KOAN) and its subsidiaries. As part of the transaction structure, MedwellAI has reserved a Preferred Series B class of stock to facilitate the share exchange and the assumption of certain Apollo liabilities. However, the completion of the acquisition remains contingent on the resolution of ongoing negotiations with Apollo’s secured creditors and debtholders. These discussions are considered a critical prerequisite that must be resolved before the transaction can officially close. While the process is moving forward, the requirement for creditor approval introduces a level of uncertainty regarding the final closing timeline. Investors in the OTC markets are closely monitoring these developments for their impact on the combined entity's future balance sheet.